Past Projects
Centre for Clinical Trials
Efficacy and safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients. [more info]
Efficacy and safety assessment of intracameral T2380 (fixed combination of lidocaine, phenylephrine and tropicamide) for anaesthesia and mydriasis in phacoemulsification cataract surgery [more info]
A phase 3 Prospective, Randomized, Double-Masked, 12-week, parallel group Study evaluating the efficacy and safety of Latanoprost and Timolol in Pediatric subjects with Glaucoma [more info]
A phase 1, Open-Label study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated with Latanoprost 0,005% [more info]
An Exploratory, Multicenter, Patient-masked, Dose-escalation, Paired-eye Comparison, Sham-controlled, 6-Month (Plus 6-Month Extension) Study to Evaluate the Safety and Effects on Visual Function of 100ug, 200 ug, and 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Retinitis Pigmentosa [more info]
A Multicenter, Investigator-Masked, Parallel-Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0,1% Eyedrops Compared with Kerorolac 0,5% Eyedrops in Ocular Inflammation After Cataract Surgery [more info]
A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration [more info]
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) [more info]
Early Markers of choroidal neovascularization (CNV) in fellow eyes of patients with Age-Related Macular Degeneration (AMD) and CNV in one eye [more info]
A phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exsudative Age-Related Macular Degeneration (AMD) [more info]